Premera Bluecross cystic fibrosis drug Coverage Update | OpenPayer
ModifiedPremera BluecrossPolicy N/A
Pharmacologic Treatment of Cystic Fibrosis
Defines medical necessity criteria, documentation, duration, and mutation-specific indications for select CF drugs (Alyftrek, Cayston, Kalydeco, Orkambi, Symdeko, Trikafta) under the pharmacy benefit for covered individuals.
Key ActionSubmit prior authorization with genotype documentation showing a mutation responsive to the requested CFTR modulator; initial approvals may be issued up to 12 months.
Updated Trikafta coverage criteria to include treatment of certain individuals with cystic fibrosis who have a mutation that is responsive to Trikafta based on clinical and/or in vitro data.
Added coverage criteria for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).
Clarified that Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta cannot be used in combination.
Added a quantity limit per the prescribing information for Kalydeco, Orkambi, Symdeko, and Trikafta.
Updated initial approval length from 6 months to 12 months.
Policy title updated from a focus on ivacaftor products to 'Pharmacologic Treatment of Cystic Fibrosis.'
6drugs with medical necessity criteria listed
12 moinitial / re-authorization maximum approval length
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Alyftrek initial criteria: Individual is aged 6 years and older AND has at least one F508del CFTR allele OR another CFTR mutation listed as responsive to Alyftrek (see Related Information) AND liver function tests (LFTs) are not above 3× upper limit of normal (ULN) AND Alyftrek will not be used in combination with Kalydeco, Orkambi, Symdeko, or Trikafta AND dose is limited to the listed fixed‑dose tablet options (three tablets of 4 mg/20 mg/50 mg or two tablets of 10 mg/50 mg/___ as specified in product labeling).age >=6 years; LFT <=3x ULN; dose limits per product labeling
Responsive mutations are enumerated in the policy's Related Information mutation tables.
Cayston initial criteria: Individual is aged 7 years and older AND has documented Pseudomonas aeruginosa infection AND baseline FEV1 is between 25% and 75% predicted AND quantity is limited to three single‑use 75 mg vials per day (one vial TID).age >=7 years; FEV1 25%–75% predicted; qty limit 3 vials/day
Indicated to improve respiratory symptoms in CF with P. aeruginosa; dosing per product labeling.
Kalydeco (ivacaftor) — Initial Therapy
Covered when ALL of the following are met
Kalydeco initial criteria: Individual is aged 1 month and older AND has at least one of the CFTR gene mutations listed in the policy table or a mutation subsequently added to the FDA‑approved ivacaftor indication AND documentation confirms at least one copy of the listed mutation AND liver function tests (LFTs) are not above 3× ULN AND Kalydeco will not be used in combination with Alyftrek, Orkambi, Symdeko, or Trikafta AND dose is limited to two tablets or two packets daily per product labeling.age >=1 month; LFT <=3x ULN; dose limit 2 tablets/packets daily
Kalydeco is considered not medically necessary for individuals homozygous for F508del.
Orkambi (lumacaftor/ivacaftor) — Initial Therapy
Covered when ALL of the following are met
Orkambi initial criteria: Individual is aged 1 year and older AND is homozygous for the F508del CFTR mutation AND liver function tests (LFTs) are not above 3× ULN AND Orkambi will not be used in combination with Alyftrek, Kalydeco, Symdeko, or Trikafta.age >=1 year; homozygous F508del; LFT <=3x ULN
Dose limits and administration follow FDA product labeling; clinical benefit was modest in TRAFFIC/TRANSPORT trials.
Symdeko (tezacaftor/ivacaftor) — Initial Therapy
Covered when ALL of the following are met
Symdeko initial criteria: Individual is aged 6 years and older AND is either homozygous for F508del OR heterozygous for F508del with a residual‑function mutation OR has at least one CFTR mutation listed as responsive to tezacaftor/ivacaftor (see Related Information) AND liver function tests (LFTs) are not above 3× ULN AND Symdeko will not be used in combination with Alyftrek, Kalydeco, Orkambi, or Trikafta.age >=6 years; LFT <=3x ULN
Responsive mutations are provided in the policy mutation tables; efficacy demonstrated modest ppFEV1 and quality‑of‑life improvements in EVOLVE/EXPAND trials.
Trikafta initial criteria: Individual is aged 2 years and older AND has at least one F508del CFTR allele OR a CFTR mutation listed as responsive to Trikafta based on clinical and/or in vitro data (see Related Information) AND liver function tests (LFTs) are not above 3× ULN AND Trikafta will not be used in combination with Alyftrek, Kalydeco, Orkambi, or Symdeko AND dose is limited to the product's specified regimen (three tablets or two packets daily per labeling).age >=2 years; LFT <=3x ULN; dose limits per product labeling
Trials demonstrated substantial ppFEV1 improvements (e.g., +13.8 at Week 4; +14.3 through Week 24) and require LFT monitoring per labeling.
Covered when the patient's CFTR genotype includes one of the mutations listed below as 'responsive' to the specified drug (evidence type noted where provided).
Alyftrek - responsive mutations: CFTR mutations listed in the policy as responsive to Alyftrek (primarily supported by in vitro and some extrapolated evidence); see the Alyftrek mutation tables in Related Information for the complete enumerated list (examples include Q493R, A559T/A559V‑associated entries, R74W;D1270 combinations, V603F and many others).mutation present
Evidence type indicated in mutation tables (in vitro or extrapolation).
Kalydeco - responsive mutations: CFTR mutations listed in the policy as responsive to ivacaftor (Kalydeco); the policy provides extensive enumerated variant mappings (see Related Information tables).mutation present
Evidence types vary by mutation (clinical or in vitro); documentation of at least one copy of the mutation is required.
Mutation-specific coverage / product evidence
Covered when ALL of the following are met (implied by mutation-specific efficacy and trial evidence):
Genotype requirement: Genetic testing documents CFTR mutation(s) that match those listed as responsive to the requested CFTR modulator (e.g., Trikafta‑responsive mutations per clinical or in vitro data).match to listed mutations
Complete enumerated mutation lists are provided in the policy's Related Information section.
Age/indication evidence: The requested CFTR modulator has clinical trial evidence and/or FDA approval for the individual's age and mutation (examples: ivacaftor efficacy for gating mutations such as G551D; Alyftrek noninferiority to Trikafta in ≥12 years and pediatric safety data in 6–11 years).age per product labeling/trials
Refer to the product‑specific trial summaries in the policy for age‑ and trial‑based evidence.
Safety monitoring:
Initial therapy coverage by product and genotype
Covered when ALL of the following are met for the specified product:
Orkambi (lumacaftor/ivacaftor): Member is homozygous for the F508del CFTR mutation AND age is within the FDA‑labeled range for Orkambi (policy notes age lowered in updates) AND clinician documents baseline status and need for therapy.homozygous F508del; age per labeling
Efficacy evidence from TRAFFIC/TRANSPORT showed modest ppFEV1 and other benefits; dose and monitoring per product labeling.
Symdeko (tezacaftor/ivacaftor): Member is homozygous for F508del OR heterozygous for F508del with at least one tezacaftor‑responsive mutation (per Related Information) AND age within the FDA‑labeled range for Symdeko AND clinician documents baseline status and need for therapy.mutation and age per labeling
EVOLVE/EXPAND trials showed modest but statistically significant ppFEV1 and QoL improvements.
Trikafta (elexacaftor/tezacaftor/ivacaftor):
Summary coverage criteria (high-level)
Covered when ALL applicable product-specific criteria in the prescribing information and policy are met (examples summarized):
General coverage conditions
Product‑specific eligibility: Individuals must meet the age and mutation criteria for the specific CFTR modulator per prescribing information (e.g., Trikafta eligibility expanded to include certain mutations supported by clinical or in vitro data).per product labeling
See the mutation tables and product sections elsewhere in the policy.
Combination restriction: Do not prescribe Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta in combination; concurrent use of these CFTR modulators is prohibited.no concomitant use
Explicit prohibition on concurrent use is specified in policy updates.
All uses of Alyftrek, Cayston, Kalydeco, Orkambi, Symdeko, or Trikafta that are not specifically described in this policy are considered investigational. The medications in this policy are subject to FDA dosing and administration instructions; requests for indications outside the policy’s outlined conditions should be treated as investigational and will not meet medical necessity.
This policy does not present separate exclusion lists beyond the mutation-specific responsiveness tables. Instead, coverage is driven by whether an individual's CFTR genotype matches one of the mutations listed as responsive to the requested CFTR modulator in the Related Information tables. Absence of a listed responsive mutation implies the request is not supported by the genotype-based criteria.
Clinical trial evidence showed that ivacaftor did not produce a significant benefit in individuals homozygous for the F508del mutation in a 16‑week trial. Consequently, use of ivacaftor (Kalydeco) for patients with homozygous F508del is not supported by this efficacy evidence and is specifically noted in the policy as not medically necessary for that genotype.
There are no standalone exclusion statements in these sections beyond the genotype-, age-, and safety-based criteria. However, where trial results show only modest or uncertain clinical benefit (for example, small absolute ppFEV1 gains), that lack of demonstrated clinically meaningful improvement may influence individual eligibility determinations during authorization reviews.
Concurrent use of the CFTR modulators listed in this policy is explicitly disallowed. Do not prescribe Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta in combination; requests for concurrent administration may be denied.
Kalydeco (ivacaftor) is designated as not medically necessary when used in individuals who are homozygous for the F508del CFTR mutation. The policy cites lack of demonstrated benefit in this subgroup as the basis for this determination.
Within the cited chunks there are no additional explicit statements labeled as 'not medically necessary' beyond the Kalydeco/F508del specification. Not medically necessary determinations are driven by the presence or absence of supportive evidence for the requested drug in the individual's genotype, age group, or clinical context.
Use of ivacaftor for individuals homozygous for F508del is not supported by the cited trial evidence: a 16‑week trial failed to show significant improvement in that subgroup. This evidence base indicates ivacaftor monotherapy is unlikely to be clinically beneficial for F508del homozygotes and therefore is not an appropriate indication for coverage.
Treatment with a CFTR modulator in the absence of genotype confirmation that the member has a mutation listed as responsive to the requested drug, or outside the drug’s FDA‑labeled age range, is not supported by the policy. Prior authorization decisions require documentation of the CFTR mutation(s) and member age consistent with the product labeling; requests lacking genotype-confirmation or outside labeled ages risk being considered not medically necessary or investigational.
The policy considers use of CFTR modulators for mutations that are not listed as responsive in FDA labeling or in the policy’s responsive-mutation tables to be unsupported unless specific clinical or in vitro evidence (as documented for Trikafta or through updated prescribing information) justifies coverage. In practice, mutations not present on the responsive lists are effectively treated as investigational for those modulators.
Coding and Clinical Thresholds
Benefit applicationmixed
No codes listed
No explicit CPT/HCPCS/ICD-10/NDC codes in this sectionmixed
No codes listed
Cayston FEV1 — 25% to 75% predicted
FEV1 range (policy requirement)FEV1 between 25% and 75% predicted is required for Cayston eligibility
Age requirementIndividual must be aged 7 years or older
Microbiologic requirementDocumented Pseudomonas aeruginosa infection is required
Quantity limitLimited to 3 vials per day (one 75 mg vial three times daily)
Liver function tests — not above 3x ULN
LFT threshold (policy requirement)Liver function tests must not be above 3× upper limit of normal (ULN)
Provider Actions, Prior Authorization, and Documentation
Prior Authorization
Prior authorization required; approval length
Pharmacy benefit prior authorization is required for initial and re-authorization requests for the CFTR modulators listed in this policy. Initial authorizations may be approved for up to 12 months. Re-authorizations may be approved for up to 12 months when documentation at the time of re-authorization shows that the coverage criteria continue to be met and the individual has demonstrated improvement in FEV1, symptoms, or stabilization of disease. Non-formulary exception review authorizations for the drugs listed may also be approved up to 12 months. Therapies must follow the product's FDA dosing and administration prescribing information.
Initial and re-authorization approvals: up to 12 months
Non-formulary exception review authorizations: may be approved up to 12 months
Must follow FDA dosing and administration
Note
Genotype-based coverage support
Coverage decisions for CFTR modulators are genotype-dependent. The policy provides mutation-to-drug responsiveness lists (e.g., extensive lists for Trikafta, and mutation lists for Alyftrek, Kalydeco, Symdeko) that support which mutations are considered responsive based on clinical and/or in vitro data. Presence of a listed responsive CFTR mutation supports medical necessity for the corresponding modulator per the policy criteria.
Background and Rationale
Cystic fibrosis is an inherited disorder caused by mutations in the CFTR gene that result in thick, sticky mucus accumulation in the lungs, digestive tract, and other organs. CFTR modulators are drugs designed to target specific CFTR gene defects to improve CFTR protein function and clinical outcomes; this policy defines mutation-, age-, and safety‑based criteria for when these agents and inhaled aztreonam (Cayston) are medically necessary under the pharmacy benefit.
Definitions and Mechanisms
CFTR modulator
DefinitionDrugs developed to target specific changes (mutations) in the CFTR gene to improve CFTR protein function and clinical outcomes.
PurposeIntended to correct or potentiate CFTR protein function depending on mechanism of action
Use in policyCoverage is mutation-specific; eligibility depends on presence of responsive CFTR mutations per product labeling and policy lists
responsive
MeaningIndicates that a given CFTR mutation has evidence (in vitro, extrapolated, or clinical) suggesting it responds to the named CFTR modulator.
Evidence typesResponsiveness classifications in the policy include clinical-data responsive and in vitro-data responsive entries
Policy Revision History
2026-04-01policy_updateLatest
Initial authorization length for CFTR modulator therapies updated from 6 months to 12 months (initial approval length increased to 12 months).
2025-05-01policy_update
Added coverage criteria for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor); expanded Trikafta eligibility to include individuals with mutations responsive based on clinical and/or in vitro data; added quantity limits per prescribing information for multiple CFTR modulators; clarified non-concomitant use of Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta.
Key ActionSubmit prior authorization with genotype documentation showing a mutation responsive to the requested CFTR modulator; initial approvals may be issued up to 12 months.
CFTR mutations listed in the policy as responsive to tezacaftor/ivacaftor (Symdeko); detailed mutation and complex allele mappings are provided in the Related Information tables.
mutation present
Includes splice and complex allele mappings; evidence may be in vitro and/or clinical.
Trikafta - responsive mutations: CFTR mutations listed in the policy as responsive to Trikafta based on clinical and/or in vitro data; the Related Information tables specify which mutations are supported by clinical data versus in vitro data (extensive enumerated list).mutation present
Some entries explicitly designate clinical‑data responsiveness vs in‑vitro responsiveness.
Baseline and periodic liver transaminase monitoring is required given potential for ALT/AST elevations; follow product labeling including boxed warnings for liver injury where present.
per product labeling
Trikafta and Alyftrek labeling include boxed warnings for drug‑induced liver injury; monitor LFTs per labeling.
Member has CF with an eligible CFTR mutation consistent with labeled indications (e.g., at least one F508del allele or another Trikafta‑responsive mutation) AND age is within the FDA‑labeled range for Trikafta (policy includes data for ages 2–5, 6–11, 12+) AND clinician provides baseline ppFEV1 and relevant documentation.
mutation and age per labeling
Trials demonstrated substantial ppFEV1 gains (e.g., +13.8 at Week 4; +14.3 through Week 24) and reduced sweat chloride; monitor LFTs as per labeling.
Applies to which productsRequirement applies to Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta per product-specific criteria
Timing/monitoring implicationBaseline and periodic liver transaminase monitoring referenced in safety sections and product labeling
Denial riskRequests may be denied if LFTs exceed 3× ULN
ppFEV1 improvement — Trikafta trial results
Trikafta Week 4 ppFEV1 change (Trial 1)Mean absolute treatment difference vs placebo: +13.8 percentage points at Week 4
Trikafta through Week 24 (Trial 1)Mean absolute change vs placebo: +14.3 percentage points through Week 24
Trikafta vs tezacaftor/ivacaftor (Trial 2)Improvement in ppFEV1 vs tezacaftor/ivacaftor: +10.0 percentage points at Week 4
Observations timingMean improvement observed at first assessment on Day 15 and sustained through study periods
Mutation lists provided for Trikafta, Alyftrek, Kalydeco, Symdeko (clinical and/or in vitro data)
Genotype evidence supports responsiveness to the requested CFTR modulator
Prior Authorization
Genotype- and age-based prior authorization
Prior authorization requests for CFTR modulators must include documentation of the individual's CFTR genotype showing mutations responsive to the requested therapy and documentation that the individual's age meets the drug's FDA‑labeled indication. Requests lacking genotype evidence or with age outside the labeled indication may be denied.
Required: genotype-confirmed CFTR mutation(s) matching responsive mutations for the requested drug
Required: age consistent with FDA-labeled indication for the product
Denial Risk
Authorization/denial: clinical criteria apply
The policy does not specify additional step-therapy sequencing or explicit operational denial criteria beyond the stated medical necessity criteria for each drug; however, requests that do not meet the medical necessity criteria (age, mutation status, LFT ≤ 3x ULN, mutually exclusive use restrictions, dosing/quantity limits) may be denied.
No additional step-therapy requirements specified in this section
Denial may occur if documented criteria (age, genotype, LFTs, dosing limits, prohibited combinations) are not met
Denial Risk
Mutation-specific coverage risk
Coverage for Trikafta-class therapies is mutation-specific; absence of a listed responsive mutation (clinical or in vitro) creates coverage risk. For requests based on in vitro responsiveness, the documented mutation must be among those listed in the policy (or subsequently added to the FDA indication) to support approval.
Mutation-specific coverage: approvals hinge on presence of listed responsive mutations
In vitro‑based responsiveness must match the policy's mutation lists or FDA labeling
Denial Risk
Potential clinical benefit scrutiny on re-authorization
Clinical benefit is considered when re-authorizing therapy. Continued authorization expects documentation of improvement in FEV1, symptom reduction, or stabilization of disease. Modest or uncertain clinical benefit (for example small absolute changes in FEV1) may prompt further review and could be a basis for denial if improvement or stabilization is not demonstrated.
Re-authorization requires documentation of clinical improvement (FEV1, symptoms) or stabilization
Modest absolute benefit may be scrutinized; lack of demonstrated benefit may trigger denial
Denial Risk
Prohibited combinations / Mutually exclusive CFTR modulator use
Concurrent use of two or more of the following CFTR modulators is prohibited and may lead to denial of the request: Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), and Trikafta (elexacaftor/tezacaftor/ivacaftor). Products are mutually exclusive and must not be used in combination.
Required documentation to support a prior authorization includes office visit notes with diagnosis and relevant history, CFTR gene mutation test results, physical examination findings, medication history, and laboratory results (including liver function tests). For re-authorization, include documentation demonstrating continued benefit or disease stabilization.
Office visit notes: diagnosis, history, physical exam, medication history
CFTR gene mutation test results (documentation of at least one copy of the mutation)
Laboratory: liver function tests (LFTs) showing ≤ 3x ULN
For re-authorization: evidence of improvement in FEV1, symptoms, or stabilization
Documentation Required
Required genetic documentation
Genetic test results must document the individual's CFTR mutation(s) and demonstrate that they match the mutations listed as responsive to the requested modulator (based on clinical and/or in vitro data) or are included in the FDA-approved indication. Verification with appropriate sequencing per test instructions is expected when recommended.
Submit genetic test report showing CFTR mutation(s) that correspond to policy-listed responsive mutations or FDA labeling
Follow laboratory test instructions for recommended verification/bi-directional sequencing when applicable
Documentation Required
Required diagnostic and demographic documentation
Diagnostic and demographic documentation must show that the individual meets indication-specific requirements: documented diagnosis of cystic fibrosis, age within the FDA-labeled range for the requested product, and relevant baseline measures (e.g., baseline ppFEV1 where applicable). LFTs must be ≤ 3x ULN at the time of request.
Diagnosis of cystic fibrosis documented in medical record
Age consistent with FDA-labeled indication for the product
Baseline clinical measures as relevant (ppFEV1) and LFTs ≤ 3x ULN
Note
Therapy selection and sequencing considerations
Therapy selection should be guided by the individual's CFTR genotype and age. The policy outlines multiple product options and notes alternatives (for example, tezacaftor/ivacaftor may be an alternative to lumacaftor/ivacaftor for some genotypes). Comparative efficacy information (e.g., modest benefits with lumacaftor/ivacaftor versus larger benefits observed with Trikafta in trials) may inform decisions. Prior authorization reviewers may consider clinical trial evidence and FDA-labeled indications when determining the most appropriate therapy for a given genotype.
Select therapy based on documented genotype and age per product labeling
Consider alternative modulators (e.g., tezacaftor/ivacaftor vs lumacaftor/ivacaftor) when appropriate
Clinical trial efficacy data (Trikafta, Alyftrek, Orkambi) may inform selection
Documentation implicationGenotype documentation showing a listed responsive mutation is expected with prior authorization requests
F508del (ΔF508)
Molecular changeDeletion of three nucleotides resulting in loss of phenylalanine at position 508 (ΔF508/F508del)
Functional consequenceCauses misfolding and intracellular degradation of CFTR protein with little to no CFTR reaching the cell surface
Epidemiology noteF508del is the most common CFTR mutation and accounts for a large proportion of CF cases globally
G551D (gating mutation)
Molecular changeAmino acid substitution (G551D) that impairs ATP-driven channel gating without reducing channel quantity at the cell membrane
Functional consequenceGreatly reduces CFTR channel gating activity leading to decreased chloride transport
Therapeutic relevanceG551D is responsive to the potentiator ivacaftor (Kalydeco)
Mechanism: potentiator and corrector actions
Ivacaftor (potentiator)Improves CFTR channel gating (increases probability of channel opening)
Lumacaftor/Tezacaftor/Elexacaftor (correctors)Improve processing and trafficking of F508del-CFTR to increase quantity of CFTR at the cell surface
Combination rationalePotentiators and correctors are combined (e.g., Trikafta) to increase both amount and function of CFTR protein
Mutation responsive to Trikafta
Basis for responsiveness classificationMutations considered responsive to Trikafta are those documented in prescribing information based on clinical and/or in vitro data
Documentation expectationPolicy lists specific CFTR mutations labeled as responsive to Trikafta with evidence type indicated where provided
Coverage implicationPresence of a Trikafta-responsive mutation supports medical necessity when other criteria are met
Policy contextThese CFTR modulators are the focus of mutation-specific coverage criteria and quantity/duration limits per prescribing information
Combination restrictionPolicy explicitly prohibits concurrent use of these listed CFTR modulators
2023-07-01
annual_review
Annual review updates: Orkambi approval updated for patients age 1 year and older; standardized terminology from 'patient' to 'individual'.
2022-11-01annual_review
Annual review completed (approved Oct 24, 2022) with updates to tables on CFTR gene mutations responsive to Kalydeco and Symdeko as noted historically.